Story
AbbVie Stock Slides as Earnings Report Triggers Profit-Taking
Shares of AbbVie Inc. (ABBV) fell 4.2% in pre-market trading Friday in a classic "sell the news" reaction to its second-quarter 2026 earnings report. The decline came after a sustained rally pushed the stock toward record highs, creating a high bar for the financial results to impress investors.
Pre-Announced Charges Weighed on Guidance
The negative reaction appears linked to guidance that the company had already signaled. In a July 6 SEC filing, AbbVie disclosed that a $291 million expense related to acquired in-process research and development (IPR&D) and milestones would impact second-quarter results.
The company stated this charge would reduce both its GAAP and adjusted diluted earnings per share (EPS) by $0.17. This led to revised guidance for Q2 adjusted EPS of $3.57–$3.61, which was below the Wall Street consensus estimate of approximately $3.77. The company's full-year adjusted EPS guidance was also revised at that time to $13.91–$14.11.
Market Reaction and Context
Despite management's prior warning about the one-time charges, AbbVie's stock continued to rally into the earnings announcement. This bullish positioning left little room for disappointment and set the stage for profit-taking. The pre-market drop of 4.2% aligns almost precisely with the move implied by options market data ahead of the release.
AdThe selling pressure is specific to AbbVie, not the result of a broader market downturn. On Friday morning, the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite were all trading higher. This indicates investors are reacting to company-specific news rather than macroeconomic factors.
Outlook Remains Focused on Fundamentals
Analysts had been largely bullish heading into the report, with firms like BMO Capital and RBC Capital recently raising their price targets. The post-earnings sell-off is seen by some observers as a reaction to short-term optics rather than a deterioration in the company's long-term fundamentals.
AbbVie's core immunology franchise, led by key drugs Skyrizi and Rinvoq, continues to be a primary driver of growth. With the stock still trading significantly above its 52-week low, the current pullback is largely interpreted as investors capitalizing on the stock's recent strong performance.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.